Verified Document

GlaxoSmithKline And AIDS Drugs In South Africa Case Study

Related Topics:

eGlaxoSmithKline As per our previous discussion, there is little doubt anymore but that our HIV / AIDS drugs are well positioned to go to the next level of modern emergent medicine. Whatever treatment modalities that will arise in the future will be ICT-based (Information Communication Technology) and will be executed in practice utilizing mHealth (mobile) practices that are part of a network of eCare (electronic), eServices, eSurvellience and eLearning structures (Sorenson et al., 2008). The past prediction appears accurate that by this year (2012), half of all people in remote but developing areas of the world will have access to mobile technology (Singh, nd). It is therefore incumbent upon GlaxoSmithKline (GSK) to establish itself as a leader in facilitating how these efforts can complement our pharmaceuticals interventions, particularly since it is now well accepted that antiretroviral interventions are the only known approach for slowing the disease progression in infected individuals. GSK's motto is Do More, Feel Better, Live Longer for a reason, and the next step for us has solid business and community grounding in the ICT medical care sector (GSK, 2012).

RECOMMENDATIONS & ANALYSIS

Because GlaxoSmithKline is not a technological company, the recommendations provided below are to allow us to undertake an assessment of the global impact potential of what our corporate structure may be able to do to facilitate the development of a plan for mAction...

It is expected that the end result will incorporate a broad array of medical, distribution, and treatment components, including at a minimum an internal exploration of the potential for the use of gene therapy and nanotechnologies that are now part of our biological studies strategies (Singh, nd). These advances will eventually play a role in mCare and our recommendations are designed to ensure the company is well placed for that future.
The following recommendations form the basis of a corporate reorganization to prepare for these eventualities. They will be undertaken using a team approach involving the entire GSK corporation as part of an eGSK transformation:

eRecommend 1: Conduct a corporate-wide assessment of the organizational potential of GSK for integrating eAction elements to the greatest predictive benefit possible (assuming we have to make some assumptions that will need to be predicted);

eRecommend 2: Use that analysis to develop a structural diagram of the key organizational elements that the company's structure offers as potential leadership domains for eAction;

eRecommend 3: Outline specifically what it would take to identify an inspirational leader for the evolution of a community-accepted structure;

eRecommend 4:Begin determining who the appropriate South African (priority one) and global partnerships organizations should be, given that a fair degree of ICT advancement in…

Sources used in this document:
E1: The first step in this process will revolve around doing further preparation on what constitutes an effective organization that is purposefully developed to take advantage of proven organizational theories (Laguerre, 2010). GSK is already well grounded in this regard, but moving to an eGSK requires contemplating how existing resources can be focused complimentarily on multiple objectives. Our goal should be to not interfere with existing operations or personnel, but instead to tag the new e-model on to what already works well. ICT has the ability to profoundly scale the impact value of what already exists, and it is clear that this project can be an exceptional example of multiple a bottom line ROI (GIIN, 2012). We should be able to extract from each department enough of what is needed for this eLearning experience to ensure that in the future it cannot be easily separated from the other profit-making priorities of the company. An appropriate eTeam (okay, enough of the e's!) will be created to mirror each of the critical departments; and space will be preserved for including either internal or external stakeholders who may be shown to otherwise be excluded because of our business configuration. The team will include lower- and upper management representatives, scientific professionals, operational experts, and creative representatives of stakeholder departments. HR and IT representatives will either be included and/or specialized technical expertise in these and other hands-on components will be made available to the team.

E2: Specific attention in regard to this recommendation will be directed at all of the corporate elements associated with governance, business operations, production, diversity and community/global integration now in place (GSK, 2012). We have established communication and flow diagrammatic representations of these sectors. In reviewing them, the oversight team will be guided by what already exists and will look toward integrating ICT with an eye toward making the organizational documents and flow patterns interactive to support further change.

E3: Our recommended guide for this element comes from the writings of Joshua C. Laguerre (2010) on how to develop leadership utilizing researched and philosophically grounded leadership theories. He bases his findings on Yukl's 2010 "Leadership in Organizations," which he supplements with the findings of other critically reviewed operational foundations. Laguerre chose Yukl because of his comprehensive and appealing definition of leadership, which incorporates the recognized important elements of effective leadership and was geared toward sustaining future leadership development via a dynamic or
Cite this Document:
Copy Bibliography Citation

Related Documents

AIDS Drugs in Africa: Glaxo's
Words: 891 Length: 2 Document Type: Term Paper

-- but Glaxo contends that Cipla violates the companies' patents and international intellectual- property agreements"(Boseley, 2002). In moral defense of its actions, Glaxo's CEO, told shareholders "Some people might see patents as the obstacle to getting medicines to patients in poorer countries. Nothing could be further from the truth....Even in countries where low cost generics are available millions of people are dying every year because they cannot obtain low

Glaxo Smith Kline GlaxoSmithKline -
Words: 4856 Length: 18 Document Type: Term Paper

He says that if the prices are still too high, the UN should offer subsidies. (Boseley, 2003) 2. Rupert Bondy - Senior Vice President and General Counsel He played a key role in the merger between Glaxo Welcome and SmithKline as well as after the merger. Bondy developed an efficient post merger legal department and he ensured legal representation to all organizational departments. (Practical Law Company, 2003) 3. John Clarke - President,

Legal and Ethical Considerations in Marketing Product Safety and...
Words: 3091 Length: 10 Document Type: Term Paper

Marketing, Product Safety, and Intellectual Property Ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety Various organizations often find themselves in the wrong side of the law when undertaking their various business practices relating to marketing and advertisement. It is the desire of every company to have its product known to as many consumers as possible. This often drives them to employ diverse marketing and advertisement

Patents in the Pharmaceutical Industry: Economics
Words: 798 Length: 2 Document Type: Term Paper

Patents in the Pharmaceutical Industry Intellectual property theft through piracy and counterfeiting has risen dramatically over the last couple of decades. As a result, the level of activity of pirates and counterfeiters has increased, and so has the scale of organizations participating in the same. The pharmaceutical industry, which forms the basis of this text, has been widely affected; more than "90% of donor-funded HIV medicines" in the market today are

Japanese-American Biopharmaceutical Industry in the 21st Century
Words: 20340 Length: 60 Document Type: Term Paper

Japanese-American Biopharmaceutical Industry in the 21st Century Optimizing Ethical Drug Availability Between These Two Pharmaceutical Superpowers" The Japanese-American biopharmaceutical industry represents an ongoing international effort between the two top pharmaceutical markets in the world. These two economic powers provide consumers with a majority share of all pharmaceuticals produced in the world. However, a number of pharmaceutical products that are currently available to U.S. residents are unavailable to Japanese consumers. From a humanitarian perspective, this

Sign Up for Unlimited Study Help

Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.

Get Started Now